The Bax/Bcl-2 ratio, as a candidate prognostic biomarker in breast cancer, indicates the degree of mitochondrial outer membrane permeabilization and, hence, cell entry for the execution phase of the apoptotic program. Here, BCL2 is linked to breast carcinoma.